Report

Idexx raises full-year earnings outlook after better-than-expected third quarter

Idexx's veterinary diagnostics growth helped offset sluggish industry demand as revenue rose 10% to about $1.21 billion.

3 Sources, ,

IDEXX Laboratories, Inc. (IDXX) price and fundamentals card. $669.75, up $118.53 (+21.5%) today. Earnings per share grew 14.7% a year over 3 years while the stock rose 16.9% a year. P/E is 47.1x vs a 2-year median of 44.2x. Panels: price +16.9% a year, 3 yrs (high $766.68 on Nov 25 '25, low $361.04 on Apr 8 '25); EPS (diluted) $4.27, +14.7% a year, 3 yrs; revenue $4.74B, +31.7% a year, 3 yrs; P/E 47.1x, 2-yr median 44.2x - range 33.8x-60.8x; free cash flow $323M, +28.4% a year, 3 yrs; book value per share $20.44, +15.8% a year, 3 yrs. Figures: P/E 47.1x, P/B 32.8x, P/S 6.4x, EPS (12 mo) $14.22, FCF yield 2.4%, PEG 3.20, Market cap $52.8B, Gross margin 62.4%, Net margin 22.0%, 52-wk high $769.98, 52-wk low $500.61, Div yield None.

TLDR

Idexx shares were up roughly 20% during November 2 trading after the company beat third-quarter expectations and raised its full-year earnings outlook. Revenue rose 10% to about $1.21 billion, with veterinary diagnostics growth helping offset sluggish industry demand.

Today's Rank

—

Not ranked yet

Combined views

2.9K

3 Sources, first seen 5h ago